Abstract
Background: High Motility Group Box Protein 1 (HMGB1) is present within all eukaryotic cells. Recently it has been found to have a profound extracellular role in inflammation. Its delayed kinetics differentiate it from other pro-inflammatory cytokines and make it an attractive target for anti-inflammatory therapy. HMGB1 targeted therapy has been found to improve survival in sepsis and reduce metastases in cancer. In parallel with these pathalogical activities, HMGB1 may play a role in tissue growth and repair. Methods: We conducted a Medline search from 1996 to the present. Inclusion criteria were articles printed in English. Results: This article offers a review of the biology of HMGB1, from its molecular structure to its involvement in disease. Conclusions: HMGB1 is a key molecule in the immune response. Its delayed kinetics make it a unique therapeutic target. Indepth knowledge of this molecule is essential for any clinician involved in the treatment of acute or chronic conditions, including cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 283-292 |
| Number of pages | 10 |
| Journal | European Surgery - Acta Chirurgica Austriaca |
| Volume | 38 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Aug 2006 |
Keywords
- Inflammation
- Wound healing
